- ►nih.gov LJ Singerman, H Masonson, M Patel, AP … - British Medical Journal, 2008 - bjo.bmj.com Methods: Two concurrent, prospective, multicentre, double-masked studies
randomised subjects with all angiographic lesion compositions of NV-AMD to
receive intravitreous pegaptanib sodium (0.3, 1 and 3 mg) or sham ... Cited by 4 - Related articles - All 9 versions
D Kook, A Wolf, AS Neubauer, C Haritoglou, … - Der Ophthalmologe, 2008 - Springer Jüngst wurde die altersbedingte Makula- degeneration (AMD) als eine
„sozioöko- nomische Zeitbombe“ in der alternden Gesellschaft beschrieben
[29]. Neue me- dikamentöseBehandlungsansätzesindje- doch in der Lage, die ... Cited by 2 - Related articles - BL Direct
[CITATION] Investigator Notification for ranibizumab: Lucentis Meta-Analysis
SE Farah - Ophthalmic surgery, lasers & imaging: the official … - ncbi.nlm.nih.gov BACKGROUND AND OBJECTIVE: Neovascular age-related macular degeneration presents
a therapeutic challenge. The efficacy of pegaptanib sodium, a selective
inhibitor of vascular endothelial growth factor 165, was examined as a ... Cited by 2 - Related articles - All 3 versions
[CITATION] Injection intravitréenne: evaluation rétrospective de la technique et des complications d'une …
- ►prsjournal.com U Schmidt-Erfurth, S Wolf - British Journal of Ophthalmology, 2008 - bjo.bmj.com Results: No severe vision loss due to ocular inflammation or uveitis occurred.
One patient had moderate vision loss (BCVA loss ⩾15 letters). Three patients
had mild/moderate uveitis. Two serious ocular adverse events occurred ... Cited by 2 - Related articles - All 6 versions
[CITATION] Arzthaftung und off label use. Information, Standard und Zulassung
